DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 119 filers reported holding DENALI THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 1.75 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2020 | $5,281,000 | +39.6% | 147,386 | -5.8% | 0.02% | +30.8% |
| Q2 2020 | $3,782,000 | -9.8% | 156,394 | -34.7% | 0.01% | -31.6% |
| Q1 2020 | $4,194,000 | +3.5% | 239,502 | +2.9% | 0.02% | +35.7% |
| Q4 2019 | $4,052,000 | -77.4% | 232,642 | -80.1% | 0.01% | -77.0% |
| Q3 2019 | $17,923,000 | -50.6% | 1,169,884 | -33.0% | 0.06% | -48.3% |
| Q2 2019 | $36,246,000 | -5.8% | 1,745,926 | +5.4% | 0.12% | -7.8% |
| Q1 2019 | $38,458,000 | +29.4% | 1,656,249 | +15.1% | 0.13% | +17.4% |
| Q4 2018 | $29,722,000 | +21.5% | 1,438,608 | +27.8% | 0.11% | +60.3% |
| Q3 2018 | $24,467,000 | +341.0% | 1,125,455 | +209.3% | 0.07% | +325.0% |
| Q2 2018 | $5,548,000 | -1.0% | 363,856 | +27.8% | 0.02% | -5.9% |
| Q1 2018 | $5,604,000 | – | 284,612 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 7,460,732 | $240,012,000 | 28.78% |
| Casdin Capital, LLC | 1,500,000 | $48,255,000 | 2.16% |
| Flagship Pioneering Inc. | 2,619,968 | $84,284,000 | 1.98% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 38,000 | $8,192,000 | 1.85% |
| Yiheng Capital Management, L.P. | 1,014,684 | $32,642,000 | 1.49% |
| SECTORAL ASSET MANAGEMENT INC | 207,100 | $6,662,000 | 1.18% |
| Artal Group S.A. | 600,000 | $19,302,000 | 0.81% |
| GILDER GAGNON HOWE & CO LLC | 2,619,217 | $84,260,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 5,369,487 | $172,736,397 | 0.73% |
| BRANDYWINE MANAGERS, LLC | 9,601 | $309,000 | 0.53% |